These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 25048383)

  • 1. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
    Leiter LA; Carr MC; Stewart M; Jones-Leone A; Scott R; Yang F; Handelsman Y
    Diabetes Care; 2014 Oct; 37(10):2723-30. PubMed ID: 25048383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
    Ahrén B; Johnson SL; Stewart M; Cirkel DT; Yang F; Perry C; Feinglos MN;
    Diabetes Care; 2014 Aug; 37(8):2141-8. PubMed ID: 24898304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
    Nauck M; Weinstock RS; Umpierrez GE; Guerci B; Skrivanek Z; Milicevic Z
    Diabetes Care; 2014 Aug; 37(8):2149-58. PubMed ID: 24742660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
    Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
    Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Nauck MA; Stewart MW; Perkins C; Jones-Leone A; Yang F; Perry C; Reinhardt RR; Rendell M
    Diabetologia; 2016 Feb; 59(2):266-74. PubMed ID: 26577795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
    Rosenstock J; Nino A; Soffer J; Erskine L; Acusta A; Dole J; Carr MC; Mallory J; Home P
    Diabetes Care; 2020 Oct; 43(10):2509-2518. PubMed ID: 32694215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
    Wysham C; Bergenstal R; Malloy J; Yan P; Walsh B; Malone J; Taylor K
    Diabet Med; 2011 Jun; 28(6):705-14. PubMed ID: 21434995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
    Shaddinger BC; Soffer J; Vlasakakis G; Shabbout M; Weston C; Nino A
    Diabetes Res Clin Pract; 2019 Jun; 152():125-134. PubMed ID: 31004676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
    Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.
    Rosenstock J; Reusch J; Bush M; Yang F; Stewart M;
    Diabetes Care; 2009 Oct; 32(10):1880-6. PubMed ID: 19592625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.
    Ji L; Agesen RM; Bain SC; Fu F; Gabery S; Geng J; Li Y; Lu Y; Luo B; Pang W; Tao Y;
    Diabetologia; 2024 Sep; 67(9):1800-1816. PubMed ID: 38985161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.
    Okuda I; Wilson TH; Yue L; Nakajima H; Carr MC; Tsuboi M; Nino A; Seino Y
    Curr Med Res Opin; 2017 Mar; 33(3):431-438. PubMed ID: 27852119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
    Bergenstal RM; Wysham C; Macconell L; Malloy J; Walsh B; Yan P; Wilhelm K; Malone J; Porter LE;
    Lancet; 2010 Aug; 376(9739):431-9. PubMed ID: 20580422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA; Hardy E; Sugg J; Parikh S;
    Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
    Hanefeld M; Herman GA; Wu M; Mickel C; Sanchez M; Stein PP;
    Curr Med Res Opin; 2007 Jun; 23(6):1329-39. PubMed ID: 17559733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.